Nvelop Therapeutics to Share the First Preclinical Data from its Novel, Humanized Particle Platform for In Vivo Delivery of Genetic Cargoes at the ASGCT Annual Meeting
09 Mayo 2024 - 6:30AM
Business Wire
Company’s DLVR-M platform uses a human
protein-derived architecture, with minimal viral proteins, for
delivery of a wide range of genetic cargos to a vast array of cell
types
Nvelop Therapeutics, a biotechnology company engineering
programmable, non-viral vehicles for the in vivo delivery of
therapeutic cargo, today announced the presentation of new
preclinical data from its DLVR-M platform at the 27th annual
meeting of the American Society of Gene & Cell Therapy (ASGCT)
in Baltimore. These data are the first from its DLVR-M platform,
one of Nvelop’s two in vivo-validated platforms currently being
developed to enable efficient and cell-specific delivery of a broad
set of therapeutic cargoes to treat a wide range of genetic
diseases.
The DLVR-M platform was developed at Massachusetts General
Hospital by gene editing pioneer J. Keith Joung, M.D., Ph.D., and
uses modular particles with few or no viral proteins to deliver a
broad range of therapeutic cargoes in vivo. These cargoes can
include CRISPR, base editor, and prime editor ribonucleoproteins.
DLVR-M has a distinct mechanism for loading cargoes within the
particles, which does not rely on viral-derived proteins.
“We are excited to share the first in vivo data on our DLVR-M
platform to further illustrate the breadth and diversity of the
highly innovative delivery technologies we are developing,” said
Jeff Walsh, Nvelop’s Chief Executive Officer. “This represents an
important advance for the delivery of genetic medicines with
intricately engineered particles that have the potential to be
fully humanized. We believe this platform will further our aim of
advancing new technologies that increase delivery efficiency,
tissue specificity and cargo diversity, and that address safety
challenges seen in some of today’s in vivo platforms.”
Presentation details
Poster title: Novel Humanized Particles for Efficient Delivery
of CRISPR and Other Gene Editors Abstract #: 1263 | Session
date/time: May 9, 2024, 12:00 p.m. - 7:00 p.m. ET
About Nvelop’s DLVR Platforms
Nvelop’s modular DLVR platforms are designed to realize the
potential of genetic medicines by addressing the limitations of
currently available delivery vehicles. DLVR-X comes from the lab of
co-founder David Liu, Ph.D., of the Broad Institute of MIT and
Harvard, and uses engineered virus-like particles for efficient in
vivo delivery of gene-editing proteins. Dr. Liu’s work on DLVR-X
has been described in the peer-reviewed journals Cell (2022) and
Nature Biotechnology (2024). DLVR-M was developed at Massachusetts
General Hospital in the lab of J. Keith Joung, M.D., Ph.D. and
Peter Cabeceiras, Ph.D., and uses modular particles with minimal
viral proteins. Both modular platforms have demonstrated the
capability to deliver a broad range of therapeutic cargoes and are
in vivo validated.
About Nvelop Therapeutics
Nvelop Therapeutics was founded in 2022 to address the challenge
of efficiently delivering therapeutic cargoes to target cells in
vivo. Nvelop’s next-generation platforms enable highly efficient
and cell-specific in vivo delivery of a wide range of cargoes to
many types of target cells. The two platforms were independently
developed in the labs of scientific co-founders and gene editing
pioneers Dr. David Liu of the Broad Institute of MIT and Harvard,
and Dr. J. Keith Joung at Massachusetts General Hospital. With its
own pipeline of therapeutics and through strategic collaborations,
Nvelop aims to use these programmable, non-viral platforms to
transform delivery for a broad range of genetic medicines and
modalities in order to treat many previously undruggable diseases.
Based in Cambridge, Mass., Nvelop is backed by top life science
investors including Newpath Partners, Atlas Venture, F-Prime
Capital, 5AM Ventures, GV, and ARCH Venture Partners. For more
information, visit www.nveloptx.com or follow us on LinkedIn, X
(Twitter), and Instagram.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240509495208/en/
Media Contact Mohana Ray Scientific Director, HDMZ Email:
mohana.ray@hdmz.com Phone: 312-506-5210
Corporate Contact Jason Glashow Glashow Strategic
Communications for Nvelop Email: jglashow@nveloptx.com Phone:
617-510-1800